{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:34:47Z","timestamp":1793799287269,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008658","name":"German Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"German Cancer Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010441","name":"Heidelberg University Medical Faculty Heidelberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021372","name":"HW & J Hector Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020027","name":"Dr Rolf M Schwiete Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009318","name":"Hermann von Helmholtz-Gemeinschaft Deutscher Forschungszentren","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhepr.2026.101964","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:58:40Z","timestamp":1784678320000},"page":"101964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["FGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine model"],"prefix":"10.1016","volume":"8","author":[{"given":"Nugzar","family":"Lekiashvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinh Kieu","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2152-6947","authenticated-orcid":false,"given":"Alexander","family":"Olkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3150-6384","authenticated-orcid":false,"given":"Yu-Le","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0887-0484","authenticated-orcid":false,"given":"Chun-Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Komkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-2276","authenticated-orcid":false,"given":"Felix J.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-1030","authenticated-orcid":false,"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-4204","authenticated-orcid":false,"given":"Michael T.","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101964_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107064","article-title":"Epidemiology of cholangiocarcinoma","volume":"51","author":"Qurashi","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101964_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib3","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101964_bib4","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101964_bib5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101964_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101964_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102170","article-title":"Targeting FGFR inhibition in cholangiocarcinoma","volume":"95","author":"Goyal","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2026.101964_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100974","article-title":"Activation of FGFR2 signaling suppresses BRCA1 and drives triple-negative mammary tumorigenesis that is sensitive to immunotherapy","volume":"8","author":"Lei","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.jhepr.2026.101964_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101964_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101964_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102627","article-title":"Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma","volume":"121","author":"Lamarca","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2026.101964_bib14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101964_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41698-022-00320-5","article-title":"Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies","volume":"6","author":"Lidsky","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jhepr.2026.101964_bib16","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101964_bib17","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1038\/s41467-024-47514-y","article-title":"FGFR inhibition blocks NF-B-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma","volume":"15","author":"Zhen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101964_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jhep.2021.02.032","article-title":"FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma","volume":"75","author":"Cristinziano","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.31799","article-title":"The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion-driven cholangiocarcinoma","volume":"74","author":"Kendre","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101964_bib20","first-page":"1142","article-title":"Kras-driven heterotopic tumor development from hepatobiliary organoids","volume":"40","author":"Ochiai","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhepr.2026.101964_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2019.04.004","article-title":"Single-cell analysis of the liver epithelium reveals dynamic heterogeneity and an essential role for YAP in homeostasis and regeneration","volume":"25","author":"Pepe-Mooney","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2026.101964_bib22","article-title":"Cell-of-origin, not oncogenic effect, determines desmoplastic immune exclusion in KRAS-driven liver cancer","author":"Liu","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhepr.2026.101964_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000632","article-title":"Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging","volume":"9","author":"Baretti","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.101964_bib24","doi-asserted-by":"crossref","first-page":"e1734","DOI":"10.1093\/oncolo\/oyae170","article-title":"FGFR2 fusion\/rearrangement is associated with favorable prognosis and immunoactivation in patients with intrahepatic cholangiocarcinoma","volume":"29","author":"Liu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.jhepr.2026.101964_bib25","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1158\/2159-8290.CD-21-1168","article-title":"EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"12","author":"Wu","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101964_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41467-024-45247-6","article-title":"The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma","volume":"15","author":"Spahn","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101964_bib27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2026.101964_bib28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","article-title":"Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance","volume":"20","author":"Calvisi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib29","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.stem.2019.04.017","article-title":"Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids","volume":"24","author":"Artegiani","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.jhepr.2026.101964_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4254\/wjh.v2.i12.419","article-title":"Pathological classification of intrahepatic cholangiocarcinoma based on a new concept","volume":"2","author":"Nakanuma","year":"2010","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"Alvaro","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101964_bib32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature13441","article-title":"Mutant IDH inhibits HNF-4\u03b1 to block hepatocyte differentiation and promote biliary cancer","volume":"513","author":"Saha","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101964_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006303","article-title":"Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma","volume":"11","author":"White","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jhepr.2026.101964_bib34","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/gutjnl-2021-326514","article-title":"Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications","volume":"72","author":"Martin-Serrano","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101964_bib35","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jhepr.2026.101964_bib36","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2026.101964_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101964_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12967-020-02219-w","article-title":"Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment?","volume":"18","author":"Cetintas","year":"2020","journal-title":"J Transl Med"},{"key":"10.1016\/j.jhepr.2026.101964_bib39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41586-023-05940-w","article-title":"PI3K\u03b2 controls immune evasion in PTEN-deficient breast tumours","volume":"617","author":"Bergholz","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2026.101964_bib40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhepr.2026.101964_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhepr.2026.101964_bib42","article-title":"Inhibition of FGFR reactivates IFN\u03b3 signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with anti-PD-1 antibodies","volume":"82","author":"Adachi","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101964_bib43","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","article-title":"Biochemical characterization of a gamma interferon-inducible cytokine (IP-10)","volume":"166","author":"Luster","year":"1987","journal-title":"J Exp Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:53:27Z","timestamp":1791244407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589555926002351"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101964","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2 fusion-driven cholangiocarcinoma is characterized by a distinct neutrophil-enriched tumor microenvironment in a syngeneic murine model","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101964"}}